Grifols 9-mth net 117.1 mln euros, in line

MADRID, Nov 4 (Reuters) - Spanish blood plasma firm Grifols
(GRLS.MC) posted a 26.1 percent rise in nine-month net profit to
117.1 million euros ($172.7 million) on Wednesday, in line with
analysts forecasts, thanks to continued robust demand for plasma
derivatives.

The company, which competes with Baxter (BAX.N) and
Australia's CSL (CSL.AX), said sales rose 14.9 percent to 689.6
million euros.
(Reporting by Tracy Rucinski; editing by Judy MacInnes)